THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

I certify that I am a healthcare professional in the US.

NO

For the treatment of moderate to severe Vasomotor Symptoms (VMS)—commonly referred to as hot flashes and night sweats—due to menopause1,2

Woman and doctor holding VEOZAH® (fezolinetant) logo fire extinguisher

HELPyourPATIENTS
ACCESS VEOZAH

VEOZAH® (fezolinetant) Savings Card

For eligible patients with commercial prescription insurance

Patients may pay $0 for the first monthly prescription and may pay as little as $30 per monthly refill*
Help your patients enroll. Tell them to visit VEOZAHsavings.com or ask a representative for Savings cards to offer patients.

Terms & Conditions

By enrolling in the VEOZAH Savings Program ("Program"), the patient acknowledges that they currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance and is good for use only with a valid prescription for VEOZAH® (fezolinetant) at the time the prescription is dispensed by the pharmacy. The Program has an annual maximum copay assistance limit of $1,300 per calendar year. After the annual maximum on copay assistance is reached, patient will be responsible for the remaining monthly out-of-pocket costs for VEOZAH. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state prescription health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of VEOZAH. This offer is not transferrable, has no cash value, and cannot be combined with any other offer, free trial, prescription savings card, or discount (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). The full value of the Program benefits is intended to pass entirely to the eligible patient. No other individual or entity (including, without limitation, third party payers, pharmacy benefit managers, or the agents of either) is entitled to receive any benefit, discount or other amount in connection with this Program. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, and Puerto Rico. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason (including to ensure that the offer is utilized solely for the patient's benefit).

VEOZAH® (fezolinetant) Savings Card
*Eligibility requirements and terms and conditions apply.
  • A patient must have a valid prescription for VEOZAH, meet the eligibility requirements, and present the VEOZAH Savings Card to their preferred pharmacy
  • The program has an annual maximum copay assistance limit of $1,300 per calendar year
  • There are no income requirements
  • The program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program

VEOZAH Support Solutions can provide information on what other savings options may be available for patients who are not eligible for the Savings Card, and can help patients on VEOZAH address potential access and affordability challenges, such as insurance-related delays.

Woman and doctor looking at iPad

VEOZAH Support Solutions can provide information on what other savings options may be available for patients who are not eligible for the Savings Card, and can help patients on VEOZAH address potential access and affordability challenges, such as insurance-related delays.

VEOZAH Support Solutions can also help with benefits verification and provide information regarding prior authorization processes and potential eligibility for various VEOZAH Support Solutions programs.

You or your patient can contact VEOZAH Support Solutions or call 1-866-239-1637

EXPLORE INSURANCE COVERAGE FOR PATIENTS WITH

No prescription insurance

The Astellas Patient Assistance Program (PAP)* provides VEOZAH at no cost to uninsured patients who meet the program eligibility requirements.

To find out if your patient is eligible, you or your patient can call VEOZAH Support SolutionsSM at 1-866-239-1637, Monday through Friday, 8:00 AM to 8:00 PM ET. Information may also be provided about other assistance options that may be available.

*Subject to eligibility restrictions. Program terms and conditions apply. Void where prohibited by law.

Medicare Part D, Medicaid, or other government insurance

Information may be provided about other assistance options that may be available, such as Medicare Extra Help.*

VEOZAH Support SolutionsSM can also help with benefits verification and provide information regarding prior authorization and/or appeal processes.

*VEOZAH Support Solutions has no control over the decisions of, and does not guarantee support from, independent third parties.

RESOURCES

Share savings and support resources with your patients

Download patient materials, such as the patient tearsheet, for VEOZAH access information.

Share savings and support resources with your patients

Download patient materials, such as the patient tearsheet, for VEOZAH access information.

Depending on your preference, there are 2 ways to submit a prescription for VEOZAH

  1. Submit the prescription directly to the patient’s preferred pharmacy. Your patient can then fill the prescription at their preferred pharmacy and begin treatment
  2. Submit the prescription electronically to the VEOZAH Support Solutions pharmacy if your patient experiences an insurance-related delay. You can submit the prescription from your electronic medical record system and select the following:

Sonexus Health Pharmacy Services
2730 S. Edmonds Lane, Suite 300
Lewisville, Texas 75067
NPI Number: 1447680210
NCPDP: 5910206

If you are having trouble sending the prescription to VEOZAH Support Solutions electronically, you can call in the prescription to 1-866-239-1637 or fax the prescription to 1-866-781-4998.

CONTACT YOUR ASTELLAS REPRESENTATIVE

Request a sales representative who can connect you with the appropriate Astellas Account Manager to help address your specific questions.

CALL VEOZAH SUPPORT SOLUTIONS TO SPEAK TO A PATIENT CARE COORDINATOR

Phone: 1-866-239-1637 Monday–Friday, 8:00 AM–8:00 PM ET

GO ONLINE

Visit VEOZAHSupportSolutions.com.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

EXPAND COLLAPSE

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

VEOZAH® (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors
INDICATIONS AND USAGE

VEOZAH® (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN) occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo in three clinical trials. No serum elevations in total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs. placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%), insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%), and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information for VEOZAH® (fezolinetant).

REFERENCES: 1. VEOZAH [package insert]. Northbrook, IL: Astellas Pharma US, Inc. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55.